MHRA flags over 150 deaths linked to weight-loss drugs as adverse reports surge
The MHRA reports more than 150 deaths linked to GLP-1 weight-loss drugs, based on around 150,000 adverse-reaction reports. Tirzepatide (Mounjaro) accounts for the majority of serious reports and near-100 fatalities; semaglutide (Wegovy) and liraglutide (Saxenda) also appear in the data. Regulators caution that reports do not prove causation and that benefits of GLP-1 medicines generally outweigh risks when used under medical supervision; manufacturers stress ongoing safety monitoring.
